Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.
Sarepta SRPT,
“We intend to continue to move forward with diligence and urgency to generate the evidence necessary to bring SRP-9001 to waiting Duchenne patients around the world,” Chief Executive Doug Ingram said in a news release Thursday afternoon.
Sarepta shares dove more than 50% following a halt on after-hours trading while the news was announced and executives held a conference call Thursday. The stock closed Thursday with a 1.5% gain at $168.95, but was trading for less than $80 in the extended session. Sarepta shares have gained nearly 30% in the past year, as the S&P 500 index SPX,
